See more : Integral Acquisition Corporation 1 (INTEU) Income Statement Analysis – Financial Results
Complete financial analysis of Cue Biopharma, Inc. (CUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cue Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Beijer Ref AB (publ) (BEIJ-B.ST) Income Statement Analysis – Financial Results
- Freedom Financial Holdings, Inc. (FDVA) Income Statement Analysis – Financial Results
- XP Chemistries AB (publ) (XPC.ST) Income Statement Analysis – Financial Results
- AMERCO (UHALB) Income Statement Analysis – Financial Results
- Resimac Group Limited (RMC.AX) Income Statement Analysis – Financial Results
Cue Biopharma, Inc. (CUE)
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 1.25M | 14.94M | 3.15M | 3.46M | 1.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 38.10M | 1.81M | -1.78M | 33.55M | 27.49M | 28.54M | 419.57K | 202.09K | 44.82K |
| Gross Profit | -32.61M | -560.83K | 16.72M | -30.39M | -24.03M | -27.40M | -419.57K | -202.09K | -44.82K |
| Gross Profit Ratio | -593.93% | -45.04% | 111.90% | -963.48% | -694.90% | -2,398.16% | 0.00% | 0.00% | 0.00% |
| Research & Development | 40.80M | 38.58M | 41.35M | 33.55M | 27.49M | 28.54M | 18.90M | 5.69M | 1.50M |
| General & Administrative | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Other Expenses | -37.94M | 0.00 | 0.00 | 0.00 | 64.00K | 165.34K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.54M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Cost & Expenses | 57.64M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Interest Income | 2.66M | 928.24K | 45.90K | 463.91K | 419.00K | 376.01K | 35.00 | 52.00 | 0.00 |
| Interest Expense | 1.25M | 713.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.44M | 1.81M | -1.78M | 1.06M | 5.35M | 760.01K | 419.57K | 202.09K | 44.82K |
| EBITDA | -46.05M | -50.49M | -45.44M | -43.99M | -35.96M | -37.94M | -22.81M | -7.46M | -1.88M |
| EBITDA Ratio | -838.83% | -4,076.94% | -292.56% | -1,394.44% | -1,063.30% | -3,320.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -52.15M | -53.22M | -43.71M | -45.04M | -36.77M | -38.70M | -23.23M | -7.66M | -1.93M |
| Operating Income Ratio | -949.89% | -4,274.31% | -292.56% | -1,427.96% | -1,063.30% | -3,386.71% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 215.00K | 45.90K | 463.91K | 482.79K | 541.35K | 35.00 | 52.00 | 0.00 |
| Income Before Tax | -50.73M | -53.01M | -43.67M | -44.58M | -36.29M | -38.16M | -23.23M | -7.66M | -1.93M |
| Income Before Tax Ratio | -924.10% | -4,257.09% | -292.25% | -1,413.26% | -1,049.33% | -3,339.33% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -214.43K | 495.00K | 206.25K | 412.00K | 825.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -50.73M | -52.80M | -44.16M | -44.78M | -36.70M | -38.98M | -23.23M | -7.66M | -1.93M |
| Net Income Ratio | -924.10% | -4,239.87% | -295.56% | -1,419.79% | -1,061.25% | -3,411.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| EPS Diluted | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| Weighted Avg Shares Out | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
| Weighted Avg Shares Out (Dil) | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2022 Results - Earnings Call Transcript
Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?
Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?
Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports